## SUPPLEMENTARY FILES:

Supplementary table S1. Operational definitions of the explanatory variables

| Variable | Definition |
|---|---|
| Demographic characteristics | |
| Children | Patients aged <15 years. |
| Adolescents | Patients aged 15-18 years. |
| WHO Region | Six regions classified by the World Health Organisation (WHO) including African Region, Region of the Americas, South-East Asia Region, European Region, Eastern Mediterranean Region, Western Pacific Region. |
| Immigrant | A person who was born outside The Netherlands with a legal residence status other than tourist or refugee. |
| Non-immigrant | A native Dutch (born in The Netherlands and both parents born in The Netherlands) or a second generation immigrant (born in The Netherlands and have at least one foreign-born parent). |
| Asylum seeker | A person who has left their home country as a political refugee and is seeking asylum elsewhere. |
| Urban | Four biggest cities of the Netherlands (The Randstad): The Hague, Utrecht, Amsterdam and Rotterdam. |
| Suburban | Provinces of the Netherlands: Groningen, Friesland, Zeeland, Drenthe, Overijssel, Gelderland, Zuid-Holland, Limburg, Utrecht, Noord-Holland, Noord-Brabant, Flevoland or other areas. |
| TB notification and clinical characteristics | |
| Active case-finding | The systematic screening for active TB cases in a predetermined high-risk group for TB. This included screening for immigrants and refugees, screening for detainees, hospital staff screening, screening for travellers after their journey from TB endemic areas, screening for patients diagnosed with HIV positive, TB-contact investigation, screening for homeless and drug addicts, periodic screening for health care worker or person working with TB risk groups, screening prior to immunosuppressive treatment, X-ray examination for patients with LTBI, and others (e.g. screening as a baseline measurement prior to BCG/ travel/ appointment investigation). |
| Passive case-finding | A patient who had experienced TB symptoms (complaints) and came to the healthcare system by their own accord. |
| Known history of TB contact | A patient who had close contact history with an infectious TB case. |
| Travel history in TB endemic area >3 months | A patient who had travelled in a country with TB incidence >100 per 100,000 population for more than three months within the past two years. |
| Pulmonary TB (PTB) | All forms of TB in the lungs, isolated tracheal or bronchus TB, laryngeal TB, and other specified respiratory TB. |
| Extrapulmonary TB (EPTB) | TB within other locations in the body than the lungs, including mediastinal lymphadenopathy, which may have included isolated EPTB or a combination of PTB and EPTB. |
| Cavitary TB | Cavitary TB involves the upper lobes of the lung and characterised by the presence of cavities in the lung tissue or enlarged air spaces. |
| BCG vaccination | A patient who had a documented medical information of vaccination history or with the presence of a Bacillus Calmette Guerin (BCG) scar. |
| Had TB symptoms | A patient who had symptoms of TB disease prior to treatment. Since 2005, only “cough complaint” was recorded in the database as TB symptoms (applicable only for patients with PTB or PTB+EPTB) |

| | |
|---|---|
| Patient's delay | The number of weeks (at least 1 week) from the onset of TB symptoms and the date of the first contact with health care related to this episode. |
| Doctor's delay | The number of weeks (at least 1 week) between the first contact with health care for TB episode and the start of TB treatment. |
| Comorbidity | Comorbidity group was composed by including patients with human immunodeficiency virus (HIV), malignancy, and other diseases (diabetes mellitus, renal insufficiency/ dialysis or organ transplantation). |
| Bacteriological characteristics | |
| Smear positive | The specimen from sputum, bronchoalveolar lavage or other body materials noted as at least +1 for acid-fast bacilli (AFB+) on microscopy using Ziehl-Neelsen stain. |
| Species of Mycobacterium | Species of Mycobacterium consists of *M. tuberculosis, M. bovis*, and other *M. tuberculosis* complex such as *M. africanum, M. microti, M. canetti* or unspecified *M. tuberculosis* complex |
| Confirmed DS-TB | A patient with a susceptible result of drug-susceptibility testing (DST) for all first-line anti-TB drugs (isoniazid, rifampicin, pyrazinamide and ethambutol). |
| Presumed DS-TB | A patient treated with first-line anti-TB drugs without sufficient information on DST results |
| Confirmed DR-TB | A patient with DST results of being resistant to at least one of the fist-line TB drugs. Confirmed DR-TB was categorised as monoresistant, polyresistant, multidrug-resistant (MDR)-, or extensively drug-resistant (XDR)-TB. |
| Treatment characteristics | |
| Retreated patient | A patient who had previously started TB treatment but was discontinued after 1 month or more. This included a patient with treatment after relapse, treatment after failure, treatment after loss to follow-up, and other previously treated cases. |
| Intermittent dosing | Anti TB-drugs dosing less than once daily during the entire course of treatment or part of the treatment. |
| Adverse drug reactions (ADRs) | Unwanted and undesirable effects of a medication defined by the treating physician, and demanding an interruption or change of the treatment regimen. ADRs included antituberculosis drug-induced liver injury (DILI), neurological disorders, mental disorders, vision disorders, drug allergy, arthralgia, and others. Any combination of ≥2 ADRs were classified as multiple ADRs. |
| Drug-induced liver injury (DILI) | DILI due to anti-TB drugs was defined as an increased levels of alanine aminotransferase >3x the upper limit of normal (ULN) in the presence of symptoms of hepatotoxicity or >5x the ULN in the absence of symptoms. |
| Treatment interruption >14 days | A patient who had interrupted treatment to more than 14 days but less than 2 months. |
| Treatment supervision by public health nurses (PHNs) | Supportive discussions with patients and their family to provide TB education as well as identification of obstacles that influence treatment adherence. The intensity of supervision by PHNs varies from daily to monthly contacts. |
| Directly observed therapy | Every dose of anti-TB drugs taken under direct observation for a period of time, provided by either PHNs or other selected third parties such as family members or home nursing services |

Source: [1,2]

Supplementary table S2. Estimated case-fatality rates stratified by specific sub-population in children and adolescents treated for TB in The Netherlands, 1993-2018

| | [α]Total, n | Deaths, n | CFR (95% CI) |
|---|---|---|---|
| Total patients | 3093 | 22 | 0.7 (0.4-1.1) |
| Stratified by age | | | |
| 0-4 years | 586 | 9 | 1.5 (0.7-2.9) |
| 5-14 years | 1049 | 3 | 0.3 (0.1-0.8) |
| 15-18 years | 1458 | 10 | 0.7 (0.3-1.3) |
| Stratified by DST | | | |
| Confirmed DS-TB | 558 | 6 | 1.1 (0.4-2.3) |
| Presumed DS-TB | 2379 | 14 | 0.6 (0.3-1.0) |
| Confirmed DR-TB | 156 | 2 | 1.3 (0.2-4.6) |
| Stratified by HIV(+) and age | | | |
| HIV(+) aged 0-4 years | 4 | 1 | 25.0 (0.6-80.6) |
| HIV(+) aged 5-14 years | 10 | 0 | 0.0 (0.0-33.6) |
| HIV(+) aged 15-18 years | 23 | 3 | 13.0 (2.8-33.6) |
| Stratified by TB localisation | | | |
| Lungs | 1310 | 8 | 0.6 (0.3-1.2) |
| CNS | 53 | 4 | 7.5 (2.1-18.2) |
| Miliary | 41 | 6 | 14.6 (5.6-29.2) |
| Stratified by BCG vaccination and age | | | |
| BCG-unvaccinated, aged 0-4 years | 405 | 3 | 0.7 (0.2-2.1) |
| BCG-unvaccinated, aged 5-14 years | 468 | 1 | 0.2 (0.0-1.2) |
| BCG-unvaccinated, aged 15-18 years | 299 | 1 | 0.3 (0.0-1.8) |

Abbreviations: BCG, Bacillus Calmette-Guerin; CFR, case fatality rate; CI, confidence interval; CNS, central nervous system; DST, drug-susceptibility testing; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; HIV, human immunodeficiency virus.
[α]Included patients who were cured, completed treatment or died; and excluded those who were LTFU or with unknown outcomes.

Supplementary table S3. Factors associated with mortality in children and adolescents treated for TB in the Netherlands using univariate logistic regression analysis

| | Died (n=22) | Alive[α] (n=3071) | OR (95% CI) | *P*-value |
|---|---|---|---|---|
| Demographic characteristics | | | | |
| Year of diagnosis[#] | 2001 (1996-2004) | 2001 (1997-2009) | 0.95 (0.89-1.01) | 0.117 |
| Year of diagnosis | | | | |
| 1993-1998 | 9 (40.9) | 967 (31.5) | 1.00 | |
| 1999-2003 | 7 (31.8) | 877 (28.6) | 0.86 (0.32-2.31) | 0.761 |
| 2004-2008 | 4 (18.2) | 456 (14.8) | 0.94 (0.29-3.08) | 0.922 |
| 2009-2013 | 2 (9.1) | 371 (12.1) | 0.58 (0.12-2.69) | 0.486 |
| 2014-2018 | 0 (0.0) | 400 (13.0) | n/a | 0.993 |
| [a]Age | | | | |
| <2 years | 2 (9.1) | 220 (7.2) | 3.17 (0.53-19.08) | 0.208 |
| 2-4 years | 7 (31.8) | 357 (11.6) | 6.84 (1.76-26.58) | 0.006 |
| 5-14 years | 3 (13.6) | 1046 (34.1) | 1.00 | - |
| 15-18 years | 10 (45.5) | 1448 (47.2) | 2.41 (0.66-8.77) | 0.183 |
| Gender | | | | |
| Male | 12 (54.5) | 1690 (55.0) | 0.98 (0.42-2.28) | 0.981 |
| Female | 10 (45.5) | 1381 (45.0) | 1.00 | |
| Born in The Netherlands | | | | |
| Yes | 7 (31.8) | 1252 (40.8) | 1.00 | |
| No | 15 (68.2) | 1795 (58.5) | 1.49 (0.61-3.68) | 0.381 |
| Unknown | 0 (0.0) | 24 (0.8) | n/a | 0.998 |
| WHO Region of birth | | | | |
| European | 8 (36.4) | 1362 (44.4) | 1.00 | |
| African | 7 (31.8) | 565 (18.4) | 2.11 (0.76-5.84) | 0.151 |
| Eastern Mediterranean | 6 (27.3) | 879 (28.6) | 1.16 (0.40-3.36) | 0.782 |
| Other regions | 1 (4.5) | 241 (7.8) | 0.71 (0.09-5.67) | 0.744 |
| Unknown | 0 (0.0) | 24 (0.8) | n/a | 0.998 |
| [a]Immigrants or asylum seekers | | | | |
| No | 7 (31.8) | 1261 (41.1) | 1.00 | |
| Yes, duration <2.5 y | 5 (22.7) | 1139 (37.1) | 0.79 (0.25-2.50) | 0.698 |
| Yes, illegal immigrants | 1 (4.5) | 22 (0.7) | 8.19 (0.97-69.41) | 0.054 |
| Yes, duration ≥2.5 y | 5 (22.7) | 502 (16.3) | 1.79 (0.57-5.68) | 0.320 |
| Yes, duration unknown | 4 (18.2) | 147 (4.8) | 4.90 (1.42-16.94) | 0.012 |
| Area of living | | | | |
| Urban | 4 (18.2) | 854 (27.8) | 1.00 | |
| Suburban | 18 (81.8) | 2217 (72.2) | 1.73 (0.58-5.14) | 0.321 |
| TB notification and clinical characteristics | | | | |
| [a]Type of case finding | | | | |
| Passive | 15 (68.2) | 1478 (48.1) | 1.00 | |
| Active | 2 (9.1) | 1511 (49.2) | 0.13 (0.03-0.57) | 0.007 |
| Unknown | 5 (22.7) | 82 (2.7) | 6.01 (2.13-16.93) | 0.001 |
| [a]Known TB contacts | | | | |
| No | 21 (95.5) | 2090 (68.1) | 9.86 (1.32-73.38) | 0.025 |
| Yes | 1 (4.5) | 981 (31.9) | 1.00 | |
| Travelling in TB endemic area >3 months | | | | |
| No | 21 (95.5) | 3044 (99.1) | 1.00 | |
| Yes | 1 (4.5) | 27 (0.9) | 5.37 (0.70-41.35) | 0.107 |
| [a,b]Site of TB disease | | | | |
| PTB | 7 (31.8) | 1291 (42.0) | 1.00 | |
| EPTB | 3 (13.6) | 1452 (47.3) | 0.38 (0.10-1.48) | 0.163 |
| PTB + EPTB | 12 (54.5) | 328 (10.7) | 6.75 (2.64-17.27) | <0.001 |
| [a,b]Main localisation of TB | | | | |
| Lungs | 8 (36.4) | 1302 (42.4) | 1.00 | |
| CNS | 4 (18.2) | 49 (1.6) | 13.29 (3.87-45.62) | <0.001 |
| Miliary | 6 (27.3) | 35 (1.1) | 27.90 (9.19-84.70) | <0.001 |

| | | | | |
|---|---|---|---|---|
| Others | 0 (0.0) | 1556 (50.7) | n/a | 0.987 |
| Unknown | 4 (18.2) | 129 (4.2) | 5.05 (1.50-16.99) | 0.009 |
| Cavitary TB | | | | |
| No | 15 (68.2) | 2711 (88.3) | 1.00 | |
| Yes | 3 (13.6) | 231 (7.5) | 2.35 (0.67-8.17) | 0.180 |
| Unknown | 4 (18.2) | 129 (4.2) | 5.60 (1.83-17.12) | 0.002 |
| [a]BCG-vaccinated | | | | |
| Yes | 6 (27.3) | 1163 (37.9) | 1.00 | |
| No | 5 (22.7) | 1167 (38.0) | 0.83 (0.25-2.73) | 0.760 |
| Unknown | 11 (50.0) | 741 (24.1) | 2.88 (1.06-7.81) | 0.038 |
| [a]Had TB symptoms | | | | |
| No | 1 (4.5) | 930 (30.3) | 1.00 | |
| Yes | 19 (86.4) | 1688 (55.0) | 10.47 (1.40-78.32) | 0.022 |
| Unknown | 2 (9.1) | 453 (14.8) | 4.10 (0.37-45.40) | 0.249 |
| Patient's delay | | | | |
| No | 1 (4.5) | 781 (25.4) | 1.00 | |
| Yes, >1 week | 6 (27.3) | 1001 (32.6) | 4.68 (0.56-38.96) | 0.153 |
| Unknown | 15 (68.2) | 1289 (42.0) | 9.09 (1.20-68.94) | 0.033 |
| Doctor's delay | | | | |
| No | 4 (18.2) | 577 (18.8) | 1.00 | |
| Yes, >1 week | 6 (27.3) | 930 (30.3) | 0.93 (0.26-3.31) | 0.912 |
| Unknown | 12 (54.5) | 1564 (50.9) | 1.11 (0.36-3.44) | 0.861 |
| Total delay (doctor + patient) | | | | |
| No | 1 (4.5) | 103 (3.4) | 1.00 | |
| Yes, >1 week | 5 (22.7) | 952 (31.0) | 0.54 (0.06-4.67) | 0.577 |
| Unknown | 16 (72.7) | 2016 (65.6) | 0.82 (0.11-6.22) | 0.846 |
| [a]Comorbidity | | | | |
| No/unknown | 16 (72.7) | 3031 (98.7) | 1.00 | |
| HIV positive | 4 (18.2) | 32 (1.0) | 23.68 (7.50-74.76) | <0.001 |
| Malignancy[µ] | 2 (9.1) | 4 (0.1) | 94.72 (16.18-554.44) | <0.001 |
| Others[µ] | 0 (0.0) | 4 (0.1) | n/a | 0.999 |
| Bacteriological characteristics | | | | |
| Sputum smear microscopy | | | | |
| Negative | 3 (13.6) | 480 (15.6) | 1.00 | |
| Positive | 8 (36.4) | 433 (14.1) | 2.96 (0.78-11.21) | 0.111 |
| Unknown/ not done | 11 (50.0) | 2158 (70.3) | 0.82 (0.23-2.93) | 0.755 |
| BAL smear microscopy | | | | |
| Negative | 2 (9.1) | 109 (3.5) | 1.00 | |
| Positive | 5 (22.7) | 104 (3.4) | 2.62 (0.50-13.80) | 0.256 |
| Unknown/ not done | 15 (68.2) | 2858 (93.1) | 0.29 (0.06-1.27) | 0.099 |
| Mycobacterial culture | | | | |
| Negative | 1 (4.5) | 319 (10.4) | 1.00 | |
| Positive | 18 (81.8) | 1734 (56.5) | 3.31 (0.44-24.89) | 0.245 |
| Unknown/ not done | 3 (13.6) | 1018 (33.1) | 0.94 (0.10-9.07) | 0.957 |
| Species of Mycobacterium | | | | |
| *M. tuberculosis* | 17 (77.3) | 1372 (44.7) | 1.00 | |
| Other *M. tuberculosis* complex | 1 (4.5) | 79 (2.6) | 1.02 (0.13-7.77) | 0.984 |
| Unknown | 4 (18.2) | 1620 (52.8) | 0.20 (0.07-0.59) | 0.004 |
| Drug susceptibility | | | | |
| Confirmed DS-TB | 6 (27.3) | 552 (18.0) | 1.00 | |
| Presumed DS-TB | 14 (63.6) | 2365 (77.0) | 0.54 (0.21-1.42) | 0.215 |
| Confirmed DR-TB | 2 (9.1) | 154 (5.0) | 1.19 (0.24-5.98) | 0.828 |
| Treatment characteristics | | | | |
| [a]Previously treated for TB | | | | |
| No | 13 (59.1) | 2796 (91.0) | 1.00 | |
| Yes | 2 (9.1) | 60 (2.0) | 7.17 (1.58-32.47) | 0.011 |
| Unknown | 7 (31.8) | 215 (7.0) | 7.00 (2.76-17.73) | <0.001 |
| Previously treated for LTBI | | | | |
| No | 3 (13.6) | 970 (31.6) | 1.00 | |
| Yes | 0 (0.0) | 78 (2.5) | n/a | 0.997 |

| | | | | |
|---|---|---|---|---|
| Unknown | 19 (86.4) | 2023 (65.9) | 3.04 (0.90-10.29) | 0.074 |
| Drug dosing schedule | | | | |
| Daily | 5 (22.7) | 1085 (35.3) | 1.00 | |
| Intermittent[μ] | 0 (0.0) | 7 (0.2) | n/a | 0.999 |
| Unknown | 17 (77.3) | 1979 (64.4) | 1.86 (0.69-5.07) | 0.222 |
| [a,c]Presence of ADR | | | | |
| No/unknown | 19 (86.4) | 2900 (94.4) | 1.00 | |
| Yes, single ADR | 1 (4.5) | 147 (4.8) | 1.04 (0.14-7.81) | 0.971 |
| Yes, multiple ADRs | 2 (9.1) | 24 (0.8) | 12.72 (2.81-57.66) | 0.001 |
| [a,c]Type of ADR | | | | |
| No/unknown | 19 (86.4) | 2900 (94.4) | 1.00 | |
| DILI | 2 (9.1) | 54 (1.8) | 5.65 (1.28-24.87) | 0.022 |
| Others | 1 (4.5) | 117 (3.8) | 1.30 (0.17-9.83) | 0.796 |
| Treatment interruption >14 days | | | | |
| No | 4 (18.2) | 1045 (34.0) | 1.00 | |
| Yes | 0 (0.0) | 42 (1.4) | n/a | 0.998 |
| Unknown | 18 (81.8) | 1984 (64.6) | 2.37 (0.80-7.02) | 0.119 |
| [a]Hospitalised ≥1 week | | | | |
| No/ <1 week | 8 (36.4) | 2153 (70.1) | 1.00 | |
| Yes | 10 (45.5) | 815 (26.5) | 3.30 (1.30-8.40) | 0.012 |
| Unknown | 4 (18.2) | 103 (3.4) | 10.45 (3.10-35.27) | <0.001 |
| DOT | | | | |
| Yes | 6 (27.3) | 827 (26.9) | 1.00 | |
| No | 16 (72.7) | 2240 (72.9) | 0.98 (0.38-2.52) | 0.974 |
| Unknown | 0 (0.0) | 4 (0.1) | n/a | 0.999 |

Data are presented as number (n) with percentages (%), unless stated otherwise: [#]median with interquartile ranges (IQR).
Abbreviations: ACF, active case finding ; ADR, adverse drug reactions; BAL, bronchoalveolar lavage; BCG, Bacillus Calmette-Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-induced liver injury; DOT, directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; LTBI, latent tuberculosis infection; n/a, not applicable; OR, odds ratio; PCF, passive case finding; PTB, pulmonary tuberculosis; R, rifampicin; Z, pyrazinamide.
[α]Included patients who achieved cure or completed treatment and excluded those who were LTFU or with unknown outcomes.
[a]Variables eligible for inclusion in multivariate analysis.
[b,c]Due to the likelihood of collinearity, only one of each of these variables was included during the development of the final multivariate model.
[μ]Excluded from multivariate analysis due to the low number of patients (<20).

Supplementary table S4. Factors associated with lost to follow-up in children and adolescents treated for TB in The Netherlands using univariate logistic regression analysis

| | LTFU (n=160) | Non-LTFU[£] (n=3071) | OR (95% CI) | *P*-value |
|---|---|---|---|---|
| Demographic characteristics | | | | |
| [a,b]Year of diagnosis[#] | 1999 (1995-2003) | 2001 (1997-2009) | 0.94 (0.92-0.97) | <0.001 |
| [a,b]Year of diagnosis | | | | |
| 1993-1998 | 67 (41.9) | 967 (31.5) | 1.00 | |
| 1999-2003 | 56 (35.0) | 877 (28.6) | 0.92 (0.64-1.33) | 0.662 |
| 2004-2008 | 14 (8.8) | 456 (14.8) | 0.44 (0.25-0.80) | 0.007 |
| 2009-2013 | 14 (8.8) | 371 (12.1) | 0.54 (0.30-0.98) | 0.043 |
| 2014-2018 | 9 (5.6) | 400 (13.0) | 0.32 (0.16-0.66) | 0.002 |
| [a]Age | | | | |
| <5 years | 24 (15.0) | 577 (18.8) | 1.28 (0.75-2.18) | 0.364 |
| 5-14 years | 34 (21.3) | 1046 (34.1) | 1.00 | |
| 15-18 years | 102 (63.7) | 1448 (47.2) | 2.17 (1.46-3.22) | <0.001 |
| [a]Gender | | | | |
| Male | 101 (63.1) | 1690 (55.0) | 1.40 (1.01-1.94) | 0.045 |
| Female | 59 (36.9) | 1381 (45.0) | 1.00 | |
| [a,c]Born in The Netherlands | | | | |
| Yes | 52 (32.5) | 1252 (40.8) | | |
| No | 108 (67.5) | 1795 (58.5) | 1.45 (1.03-2.03) | 0.032 |
| Unknown | 0 (0.0) | 24 (0.8) | n/a | 0.998 |
| [a,c]WHO Region of birth | | | | |
| European | 64 (40.0) | 1362 (44.4) | 1.00 | |
| African | 28 (17.5) | 565 (18.4) | 1.05 (0.67-1.66) | 0.819 |
| Eastern Mediterranean | 57 (35.6) | 879 (28.6) | 1.38 (0.96-1.99) | 0.085 |
| Americas | 0 (0.0) | 56 (1.8) | n/a | 0.997 |
| South-East Asian | 2 (1.3) | 79 (2.6) | 0.54 (0.13-2.24) | 0.395 |
| Western Pacific | 9 (5.6) | 105 (3.4) | 1.82 (0.88-3.77) | 0.104 |
| Unknown | 0 (0.0) | 25 (0.8) | n/a | 0.998 |
| [a]Immigrants or asylum seekers | | | | |
| No | 51 (31.9) | 1261 (41.1) | 1.00 | |
| Yes, duration <2.5 y | 71 (44.4) | 1139 (37.1) | 1.54 (1.07-2.23) | 0.021 |
| Yes, illegal immigrants | 8 (5.0) | 22 (0.7) | 8.99 (3.82-21.17) | <0.001 |
| Yes, duration ≥2.5 y | 17 (10.6) | 502 (16.3) | 0.84 (0.48-1.46) | 0.533 |
| Yes, duration unknown | 13 (8.1) | 147 (4.8) | 2.19 (1.16-4.12) | 0.015 |
| [a]Area of living | | | | |
| Urban | 59 (36.9) | 854 (27.8) | 1.52 (1.09-2.11) | 0.014 |
| Suburban | 101 (63.1) | 2217 (72.2) | 1.00 | |
| TB notification and clinical characteristics | | | | |
| Type of case finding | | | | |
| Passive | 85 (53.1) | 1478 (48.1) | 1.00 | |
| Active | 66 (41.3) | 1511 (49.2) | 0.76 (0.55-1.06) | 0.102 |
| Unknown | 9 (5.6) | 82 (2.7) | 1.91 (0.93-3.93) | 0.079 |
| [a]Known TB contacts | | | | |
| No | 135 (84.4) | 2090 (68.1) | 2.53 (1.64-3.91) | <0.001 |
| Yes | 25 (15.6) | 981 (31.9) | 1.00 | |
| Travelling in TB endemic area >3 months | | | | |
| No | 158 (98.8) | 3044 (99.1) | 1.00 | |
| Yes | 2 (1.3) | 27 (0.9) | 1.43 (0.34-6.05) | 0.630 |
| Site of TB disease | | | | |
| PTB | 67 (41.9) | 1291 (42.0) | 1.00 | |
| EPTB | 71 (44.4) | 1452 (47.3) | 0.94 (0.67-1.33) | 0.733 |
| PTB + EPTB | 22 (13.8) | 328 (10.7) | 1.29 (0.79-2.12) | 0.311 |
| [a]Main localisation of TB | | | | |
| Primary TB infection | 21 (13.1) | 673 (21.9) | 0.56 (0.34-0.93) | 0.023 |
| Lungs | 72 (45.0) | 1302 (42.4) | 1.00 | |

| | | | | |
|---|---|---|---|---|
| Respiratory tract | 16 (10.0) | 388 (12.6) | 0.75 (0.43-1.30) | 0.299 |
| CNS | 1 (0.6) | 49 (1.6) | 0.37 (0.05-2.71) | 0.327 |
| Abdominal | 4 (2.5) | 51 (1.7) | 1.42 (0.50-4.03) | 0.512 |
| Osteoarticular | 5 (3.1) | 67 (2.2) | 1.35 (0.53-3.45) | 0.532 |
| Other organs | 24 (15.0) | 377 (12.3) | 1.15 (0.71-1.85) | 0.562 |
| Miliary | 2 (1.3) | 35 (1.1) | 1.03 (0.24-4.38) | 0.965 |
| Unknown | 15 (9.4) | 129 (4.2) | 2.10 (1.17-3.77) | 0.013 |
| Cavitary TB | | | | |
| No | 132 (82.5) | 2711 (88.3) | 1.00 | |
| Yes | 13 (8.1) | 231 (7.5) | 1.16 (0.64-2.07) | 0.628 |
| Unknown | 15 (9.4) | 129 (4.2) | 2.39 (1.36-4.19) | 0.002 |
| BCG-vaccinated | | | | |
| Yes | 58 (36.3) | 1163 (37.9) | 1.00 | |
| No | 52 (32.5) | 1167 (38.0) | 0.89 (0.61-1.31) | 0.564 |
| Unknown | 50 (31.3) | 741 (24.1) | 1.35 (0.92-2.00) | 0.128 |
| Had TB symptoms | | | | |
| No | 49 (30.6) | 930 (30.3) | 1.00 | |
| Yes | 93 (58.1) | 1688 (55.0) | 1.05 (0.73-1.49) | 0.805 |
| Unknown | 18 (11.3) | 453 (14.8) | 0.75 (0.43-1.31) | 0.316 |
| Patient's delay | | | | |
| No | 46 (28.7) | 781 (25.4) | 1.00 | |
| Yes, 1-4 weeks | 25 (15.6) | 608 (19.8) | 0.70 (0.42-1.15) | 0.158 |
| Yes, 5-8 weeks | 12 (7.5) | 168 (5.5) | 1.21 (0.63-2.34) | 0.565 |
| Yes, >8 weeks | 11 (6.9) | 225 (7.3) | 0.83 (0.42-1.63) | 0.588 |
| Unknown | 66 (41.3) | 1289 (42.0) | 0.87 (0.59-1.28) | 0.478 |
| Doctor's delay | | | | |
| No | 33 (20.6) | 577 (18.8) | 1.00 | |
| Yes, 1-4 weeks | 33 (20.6) | 556 (18.1) | 1.04 (0.63-1.70) | 0.884 |
| Yes, 5-8 weeks | 10 (6.3) | 137 (4.5) | 1.28 (0.61-2.65) | 0.513 |
| Yes, >8 weeks | 12 (7.5) | 237 (7.7) | 0.88 (0.45-1.74) | 0.725 |
| Unknown | 72 (45.0) | 1564 (50.9) | 0.80 (0.53-1.23) | 0.315 |
| Total delay (doctor + patient) | | | | |
| No | 6 (3.8) | 103 (3.4) | 1.00 | |
| Yes, 1-4 weeks | 23 (14.4) | 332 (10.8) | 1.19 (0.47-3.00) | 0.714 |
| Yes, 5-8 weeks | 9 (5.6) | 206 (6.7) | 0.75 (0.26-2.16) | 0.595 |
| Yes, >8 weeks | 24 (15.0) | 414 (13.5) | 0.99 (0.40-2.50) | 0.992 |
| Unknown | 98 (61.3) | 2016 (65.6) | 0.83 (0.36-1.95) | 0.676 |
| Comorbidity | | | | |
| No/unknown | 158 (98.8) | 3031 (98.7) | 1.00 | |
| HIV positive | 0 (0.0) | 32 (1.0) | n.a | 0.998 |
| Malignancy | 1 (0.6) | 4 (0.1) | 4.80 (0.53-43.16) | 0.162 |
| Others | 1 (0.6) | 4 (0.1) | 4.80 (0.53-43.16) | 0.162 |
| Bacteriological characteristics | | | | |
| Sputum smear microscopy | | | | |
| Negative | 25 (15.6) | 480 (15.6) | 1.00 | |
| Positive | 18 (11.3) | 433 (14.1) | 0.80 (0.43-1.48) | 0.476 |
| Unknown/ not done | 117 (73.1) | 2158 (70.3) | 1.04 (0.67-1.62) | 0.859 |
| BAL smear microscopy | | | | |
| Negative | 6 (3.8) | 109 (3.5) | 1.00 | |
| Positive | 3 (1.9) | 104 (3.4) | 0.52 (0.13-2.15) | 0.370 |
| Unknown/ not done | 151 (94.4) | 2858 (93.1) | 0.96 (0.41-2.22) | 0.924 |
| Mycobacterial culture | | | | |
| Negative | 13 (8.1) | 319 (10.4) | 1.00 | |
| Positive | 104 (65.0) | 1734 (56.5) | 1.47 (0.82-2.65) | 0.198 |
| Unknown/ not done | 43 (26.9) | 1018 (33.1) | 1.04 (0.55-1.95) | 0.912 |
| Species of Mycobacterium | | | | |
| *M. tuberculosis* | 77 (48.1) | 1372 (44.7) | 1.00 | |
| Other *M. tuberculosis* complex | 4 (2.5) | 79 (2.6) | 0.90 (0.32-2.53) | 0.845 |
| Unknown | 79 (49.4) | 1620 (52.8) | 0.87 (0.63-0.20) | 0.392 |
| [a]Drug susceptibility | | | | |

| | | | | |
|---|---|---|---|---|
| Confirmed DS-TB | 16 (10.0) | 552 (18.0) | 1.00 | |
| Presumed DS-TB | 127 (79.4) | 2365 (77.0) | 1.85 (1.09-3.14) | 0.022 |
| Confirmed DR-TB | 17 (10.6) | 154 (5.0) | 3.81 (1.88-7.71) | <0.001 |
| Treatment characteristics | | | | |
| Previously treated for TB | | | | |
| No | 140 (87.5) | 2796 (91.0) | 1.00 | |
| Yes | 6 (3.8) | 60 (2.0) | 2.00 (0.85-4.70) | 0.113 |
| Unknown | 14 (8.8) | 215 (7.0) | 1.30 (0.74-2.29) | 0.363 |
| Previously treated for LTBI | | | | |
| No | 29 (18.1) | 970 (31.6) | 1.00 | |
| Yes | 3 (1.9) | 78 (2.5) | 1.29 (0.38-4.32) | 0.683 |
| Unknown | 128 (80.0) | 2023 (65.9) | 2.12 (1.40-3.19) | <0.001 |
| [a]Drug dosing schedule | | | | |
| Daily | 30 (18.8) | 1085 (35.3) | 1.00 | |
| Intermittent[µ] | 3 (1.9) | 7 (0.2) | 15.50 (3.82-62.87) | <0.001 |
| Unknown | 127 (79.4) | 1979 (64.4) | 2.32 (1.55-3.48) | <0.001 |
| [a,d]Presence of ADR | | | | |
| No/unknown | 130 (81.3) | 2900 (94.4) | 1.00 | |
| Yes, single ADR | 19 (11.9) | 147 (4.8) | 2.88 (1.73-4.80) | <0.001 |
| Yes, multiple ADRs | 11 (6.9) | 24 (0.8) | 10.22 (4.90-21.32) | <0.001 |
| [a,d]Type of ADR | | | | |
| No/unknown | 130 (81.3) | 2900 (94.4) | 1.00 | |
| DILI | 7 (4.4) | 54 (1.8) | 2.89 (1.29-6.48) | 0.010 |
| Others | 23 (14.4) | 117 (3.8) | 4.38 (2.71-7.09) | <0.001 |
| [a]Treatment interruption >14 days | | | | |
| No | 20 (12.5) | 1045 (34.0) | 1.00 | |
| Yes | 10 (6.3) | 42 (1.4) | 12.44 (5.48-28.23) | <0.001 |
| Unknown | 130 (81.3) | 1984 (64.6) | 3.42 (2.13-5.51) | <0.001 |
| Hospitalised ≥1 week | | | | |
| No/ <1 week | 106 (66.3) | 2153 (70.1) | 1.00 | |
| Yes | 42 (26.3) | 815 (26.5) | 1.05 (0.73-1.51) | 0.807 |
| Unknown | 12 (7.5) | 103 (3.4) | 2.37 (1.26-4.44) | 0.007 |
| [a]Supervised by PHNs | | | | |
| No | 12 (7.5) | 34 (1.1) | 1.00 | |
| Yes | 141 (88.1) | 2976 (96.9) | 0.13 (0.07-0.26) | <0.001 |
| Unknown | 7 (4.4) | 61 (2.0) | 0.32 (0.12-0.90) | 0.031 |
| [a]DOT | | | | |
| Yes | 32 (20.0) | 827 (26.9) | 1.00 | |
| No | 127 (79.4) | 2240 (72.9) | 1.46 (0.99-2.18) | 0.059 |
| Unknown | 1 (0.6) | 4 (0.1) | 6.46 (0.70-59.46) | 0.099 |

Data are presented as number (n) with percentages, unless stated otherwise: [#]median with interquartile ranges (IQR).
Abbreviations: ADR, adverse drug reactions; BAL, bronchoalveolar lavage; BCG, Bacillus Calmette Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-induced liver injury; DOT, directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; LTFU, lost to follow-up; LTBI, latent tuberculosis infection; n/a, not applicable; OR, odds ratio; PHNs, public health nurses; PTB, pulmonary tuberculosis; R, rifampicin; Z, pyrazinamide.
[£]Included patients who achieved cure or completed treatment and excluded those who died or with unknown outcomes.
[a]Variable eligible for inclusion in multivariate analysis.
[b,c,d]Due to the likelihood of collinearity, only one of each of these variables was included during the development of the final multivariate model.
[µ]Excluded from multivariate analysis due to the low number of patients (<20).

Supplementary table S5. Factors associated with unfavourable outcome in children and adolescents treated for TB in The Netherlands using univariate logistic regression analysis

| | Unfavourable[¥] (n=325) | Favourable[β] (n=3071) | OR (95% CI) | *P*-value |
|---|---|---|---|---|
| Demographic characteristics | | | | |
| [a,b]Year of diagnosis[#] | 2000 (1995-2003) | 2001 (1997-2009) | 0.95 (0.93-0.96) | <0.001 |
| [a,b]Year of diagnosis | | | | |
| 1993-1998 | 125 (38.5) | 967 (31.5) | 1.00 | |
| 1999-2003 | 128 (39.4) | 877 (28.6) | 1.13 (0.87-1.47) | 0.365 |
| 2004-2008 | 29 (8.9) | 456 (14.8) | 0.49 (0.32-0.75) | 0.001 |
| 2009-2013 | 27 (8.3) | 371 (12.1) | 0.56 (0.36-0.87) | 0.009 |
| 2014-2018 | 16 (4.9) | 400 (13.0) | 0.31 (0.18-0.53) | <0.001 |
| [a]Age | | | | |
| <5 years | 61 (16.8) | 577 (18.8) | 1.38 (0.98-1.96) | 0.069 |
| 5-14 years | 80 (24.6) | 1046 (34.1) | 1.00 | |
| 15-18 years | 184 (56.6) | 1448 (47.2) | 1.66 (1.26-2.19) | <0.001 |
| [a]Gender | | | | |
| Male | 203 (62.5) | 1690 (55.0) | 1.36 (1.07-1.72) | 0.011 |
| Female | 122 (37.5) | 1381 (45.0) | 1.00 | |
| [a,c]Born in The Netherlands | | | | |
| Yes | 98 (30.2) | 1252 (40.8) | 1.00 | |
| No | 222 (68.3) | 1795 (58.5) | 1.58 (1.23-2.03) | <0.001 |
| Unknown | 5 (1.5) | 24 (0.8) | 2.66 (0.99-7.13) | 0.051 |
| [a,c]WHO Region of birth | | | | |
| European | 118 (36.3) | 1362 (44.4) | 1.00 | |
| African | 62 (19.1) | 565 (18.4) | 1.27 (0.92-1.75) | 0.151 |
| Eastern Mediterranean | 117 (36.0) | 879 (28.6) | 1.54 (1.17-2.01) | 0.002 |
| Americas | 1 (0.3) | 56 (1.8) | 0.21 (0.03-1.50) | 0.119 |
| South-East Asian | 6 (1.8) | 79 (2.6) | 0.88 (0.37-2.05) | 0.762 |
| Western Pacific | 16 (4.9) | 105 (3.4) | 1.76 (1.01-3.07) | 0.048 |
| Unknown | 5 (1.5) | 25 (0.8) | 2.31 (0.87-6.14) | 0.094 |
| [a]Immigrants or asylum seekers | | | | |
| No | 98 (30.2) | 1261 (41.1) | 1.00 | |
| Yes, duration <2.5 y | 134 (41.2) | 1139 (37.1) | 1.51 (1.15-1.99) | 0.003 |
| Yes, illegal immigrants | 17 (5.2) | 22 (0.7) | 9.94 (5.11-19.34) | <0.001 |
| Yes, duration ≥2.5 y | 37 (11.4) | 502 (16.3) | 0.95 (0.64-1.40) | 0.791 |
| Yes, duration unknown | 39 (12.0) | 147 (4.8) | 3.41 (2.27-5.14) | <0.001 |
| Area of living | | | | |
| Urban | 85 (26.2) | 854 (27.8) | 0.92 (0.71-1.19) | 0.526 |
| Suburban | 240 (73.8) | 2217 (72.2) | 1.00 | |
| TB notification and clinical characteristics | | | | |
| [a]Type of case finding | | | | |
| Passive | 170 (52.3) | 1478 (48.1) | 1.00 | |
| Active | 136 (41.8) | 1511 (49.2) | 0.78 (0.62-0.99) | 0.042 |
| Unknown | 19 (5.8) | 82 (2.7) | 2.01 (1.19-3.40) | 0.009 |
| [a]Known TB contacts | | | | |
| No | 274 (84.3) | 2090 (68.1) | 2.52 (1.85-3.43) | <0.001 |
| Yes | 51 (15.7) | 981 (31.9) | 1.00 | |
| Travelling in TB endemic area >3 months | | | | |
| No | 321 (98.8) | 3044 (99.1) | 1.00 | |
| Yes | 4 (1.2) | 27 (0.9) | 1.40 (0.49-4.04) | 0.528 |
| [a,d]Site of TB disease | | | | |
| PTB | 163 (50.2) | 1291 (42.0) | 1.00 | |
| EPTB | 118 (36.3) | 1452 (47.3) | 0.64 (0.50-0.82) | 0.001 |
| PTB + EPTB | 44 (13.5) | 328 (10.7) | 1.06 (0.74-1.51) | 0.737 |
| [a,d]Main localisation of TB | | | | |
| Primary TB infection | 30 (9.2) | 673 (21.9) | 0.54 (0.36-0.82) | 0.004 |
| Lungs | 107 (32.9) | 1302 (42.4) | 1.00 | |

| | | | | |
|---|---|---|---|---|
| Respiratory tract | 18 (5.5) | 388 (12.6) | 0.56 (0.34-0.94) | 0.029 |
| CNS | 7 (2.2) | 49 (1.6) | 1.74 (0.77-3.93) | 0.184 |
| Abdominal | 6 (1.8) | 51 (1.7) | 1.43 (0.60-3.41) | 0.418 |
| Osteoarticular | 6 (1.8) | 67 (2.2) | 1.09 (0.46-2.57) | 0.844 |
| Other organs | 33 (10.2) | 377 (12.3) | 1.06 (0.71-1.60) | 0.761 |
| Miliary | 9 (2.8) | 35 (1.1) | 3.13 (1.46-6.68) | 0.003 |
| Unknown | 109 (33.5) | 129 (4.2) | 10.28 (7.45-14.19) | <0.001 |
| Cavitary TB | | | | |
| No | 197 (60.6) | 2711 (88.3) | 1.00 | |
| Yes | 19 (5.8) | 231 (7.5) | 1.13 (0.69-1.85) | 0.620 |
| Unknown | 109 (33.5) | 129 (4.2) | 11.63 (8.67-15.59) | <0.001 |
| BCG-vaccinated | | | | |
| Yes | 117 (36.0) | 1163 (37.9) | 1.00 | |
| No | 107 (32.9) | 1167 (38.0) | 0.91 (0.69-1.20) | 0.508 |
| Unknown | 101 (31.1) | 741 (24.1) | 1.35 (1.02-1.80) | 0.035 |
| Had TB symptoms | | | | |
| No | 93 (28.6) | 930 (30.3) | 1.00 | |
| Yes | 199 (61.2) | 1688 (55.0) | 1.18 (0.91-1.53) | 0.213 |
| Unknown | 33 (10.2) | 453 (14.8) | 0.73 (0.48-1.10) | 0.132 |
| Patient's delay | | | | |
| No | 88 (27.1) | 781 (25.4) | 1.00 | |
| Yes, 1-4 weeks | 54 (16.6) | 608 (19.8) | 0.79 (0.55-1.12) | 0.189 |
| Yes, 5-8 weeks | 24 (7.4) | 168 (5.5) | 1.27 (0.78-2.05) | 0.334 |
| Yes, >8 weeks | 24 (7.4) | 225 (7.3) | 0.95 (0.59-1.52) | 0.821 |
| Unknown | 135 (41.5) | 1289 (42.0) | 0.93 (0.70-1.23) | 0.612 |
| Doctor's delay | | | | |
| No | 56 (17.2) | 577 (18.8) | 1.00 | |
| Yes, 1-4 weeks | 72 (22.2) | 556 (18.1) | 1.33 (0.92-1.93) | 0.125 |
| Yes, 5-8 weeks | 19 (5.8) | 137 (4.5) | 1.43 (0.82-2.48) | 0.206 |
| Yes, >8 weeks | 21 (6.5) | 237 (7.7) | 0.91 (0.54-1.54) | 0.733 |
| Unknown | 157 (48.3) | 1564 (50.9) | 1.03 (0.75-1.42) | 0.836 |
| Total delay (doctor + patient) | | | | |
| No | 9 (2.8) | 103 (3.4) | 1.00 | |
| Yes, 1-4 weeks | 40 (12.3) | 332 (10.8) | 1.38 (0.65-2.94) | 0.405 |
| Yes, 5-8 weeks | 20 (6.2) | 206 (6.7) | 1.11 (0.49-2.53) | 0.802 |
| Yes, >8 weeks | 49 (15.1) | 414 (13.5) | 1.35 (0.64-2.85) | 0.423 |
| Unknown | 207 (63.7) | 2016 (65.6) | 1.17 (0.59-2.36) | 0.650 |
| [a]Comorbidity | | | | |
| No/unknown | 314 (96.6) | 3031 (98.7) | 1.00 | |
| HIV positive | 7 (2.2) | 32 (1.0) | 2.11 (0.92-4.82) | 0.076 |
| Malignancy[μ] | 3 (0.9) | 4 (0.1) | 7.24 (1.61-32.49) | 0.010 |
| Others | 1 (0.3) | 4 (0.1) | 2.41 (0.27-21.66) | 0.431 |
| Bacteriological characteristics | | | | |
| Sputum smear microscopy | | | | |
| Negative | 58 (17.8) | 480 (15.6) | 1.00 | |
| Positive | 46 (14.2) | 433 (14.1) | 0.88 (0.58-1.32) | 0.536 |
| Unknown/ not done | 221 (68.0) | 2158 (70.3) | 0.85 (0.62-1.15) | 0.289 |
| BAL smear microscopy | | | | |
| Negative | 16 (4.9) | 109 (3.5) | 1.00 | |
| Positive | 15 (4.6) | 104 (3.4) | 0.98 (0.46-2.09) | 0.964 |
| Unknown/ not done | 294 (90.5) | 2858 (93.1) | 0.70 (0.41-1.20) | 0.195 |
| [a,e]Mycobacterial culture | | | | |
| Negative | 21 (6.5) | 319 (10.4) | 1.00 | |
| Positive | 187 (57.5) | 1734 (56.5) | 1.64 (1.03-2.61) | 0.038 |
| Unknown/ not done | 117 (36.0) | 1018 (33.1) | 1.75 (1.08-2.82) | 0.023 |
| [a,e]Species of Mycobacterium | | | | |
| *M. tuberculosis* | 151 (46.5) | 1372 (44.7) | 1.00 | |
| *M. bovis* | 5 (1.5) | 18 (0.6) | 2.52 (0.92-6.89) | 0.071 |
| Other *M. tuberculosis* complex | 3 (0.9) | 61 (2.0) | 0.45 (0.14-1.44) | 0.178 |
| Unknown | 166 (51.1) | 1620 (52.8) | 0.93 (0.74-1.17) | 0.546 |

| | | | | |
|---|---|---|---|---|
| [a]Drug susceptibility | | | | |
| Confirmed DS-TB | 39 (12.0) | 552 (18.0) | 1.00 | |
| Presumed DS-TB | 260 (80.0) | 2365 (77.0) | 1.56 (1.10-2.21) | 0.013 |
| Confirmed DR-TB | 26 (8.0) | 154 (5.0) | 2.39 (1.41-4.05) | 0.001 |
| Treatment characteristics | | | | |
| [a]Previously treated for TB | | | | |
| No | 273 (84.0) | 2796 (91.0) | 1.00 | |
| Yes | 13 (4.0) | 60 (2.0) | 2.22 (1.20-4.09) | 0.011 |
| Unknown | 39 (12.0) | 215 (7.0) | 1.86 (1.29-2.67) | 0.001 |
| Previously treated for LTBI | | | | |
| No | 54 (16.6) | 970 (31.6) | 1.00 | |
| Yes | 4 (1.2) | 78 (2.5) | 0.92 (0.32-2.61) | 0.877 |
| Unknown | 267 (82.2) | 2023 (65.9) | 2.37 (1.75-3.21) | <0.001 |
| [a]Drug dosing schedule | | | | |
| Daily | 56 (17.2) | 1085 (35.3) | 1.00 | |
| Intermittent[μ] | 3 (0.9) | 7 (0.2) | 8.30 (2.09-32.97) | 0.003 |
| Unknown | 266 (81.8) | 1979 (64.4) | 2.60 (1.93-3.51) | <0.001 |
| [a,f]Presence of ADR | | | | |
| No/unknown | 291 (89.5) | 2900 (94.4) | 1.00 | |
| Yes, single ADR | 20 (6.2) | 147 (4.8) | 1.36 (0.84-2.20) | 0.216 |
| Yes, multiple ADRs | 14 (4.3) | 24 (0.8) | 5.81 (2.97-11.36) | <0.001 |
| [a,f]Type of ADR | | | | |
| No/unknown | 291 (89.5) | 2900 (94.4) | 1.00 | |
| DILI | 9 (2.8) | 54 (1.8) | 1.66 (0.81-3.40) | 0.165 |
| Others | 25 (7.7) | 117 (3.8) | 2.13 (1.36-3.33) | 0.001 |
| [a]Treatment interruption >14 days | | | | |
| No | 42 (12.9) | 1045 (34.0) | 1.00 | |
| Yes | 11 (3.4) | 42 (1.4) | 6.52 (3.13-13.55) | <0.001 |
| Unknown | 272 (83.7) | 1984 (64.6) | 3.41 (2.44-4.76) | <0.001 |
| [a]Hospitalised ≥1 week | | | | |
| No/ <1 week | 238 (73.2) | 2153 (70.1) | 1.00 | |
| Yes | 68 (20.9) | 815 (26.5) | 0.75 (0.57-1.00) | 0.050 |
| Unknown | 19 (5.8) | 103 (3.4) | 1.67 (1.01-2.77) | 0.048 |
| [a]Supervised by PHNs | | | | |
| No | 32 (9.8) | 34 (1.1) | 1.00 | |
| Yes | 192 (59.1) | 2976 (96.9) | 0.07 (0.04-0.11) | <0.001 |
| Unknown | 101 (31.1) | 61 (2.0) | 1.76 (0.99-3.14) | 0.055 |
| [a]DOT | | | | |
| Yes | 50 (15.4) | 827 (26.9) | 1.00 | |
| No | 271 (83.4) | 2240 (72.9) | 2.00 (1.46-2.73) | <0.001 |
| Unknown | 4 (1.2) | 4 (0.1) | 16.54 (4.02-68.09) | <0.001 |

Data are presented as number (n) with percentages, unless stated otherwise: [#]median with interquartile ranges (IQR).

Abbreviations: ADR, adverse drug reactions; BAL, bronchoalveolar lavage; BCG, Bacillus Calmette Guerin; CI, confidence interval; CNS, central nervous system; DILI, drug-induced liver injury; DOT, directly observed therapy; DS-TB, drug-susceptible tuberculosis; DR-TB, drug-resistant tuberculosis; E, ethambutol; EPTB, extra-pulmonary tuberculosis; H, isoniazid; HIV, human immunodeficiency virus; LTBI, latent tuberculosis infection; OR, odds ratio; PHNs, public health nurses; PTB, pulmonary tuberculosis; R, rifampicin; Z, pyrazinamide.

[β]The sum of patients who achieved cure or completed treatment.

[¥]The sum of patients who died, were LTFU, or with unknown outcomes.

[a]Variable eligible for inclusion in multivariate analysis.

[b,c,d,e,f]Due to the likelihood of collinearity, only one of each of these variables was included during the development of the final multivariate model.

[μ]Excluded from multivariate analysis due to the low number of patients (<20).

**References for supplementary files:**


1. Nederlandse Vereniging van Artsen voor Longziekten en Tuberculose (NVALT). *Richtlijn Medicamenteuze Behandeling van Tuberculose*.; 2014. https://www.kncvtbc.org/uploaded/2015/09/3.4_tuberculose.pdf.
2. National Institute for Public Health and the Environment (RIVM). Osiris-NTR Tuberculose ziekte: Vragenlijst en handleiding 2017. https://www.rivm.nl/documenten/osiris-ntr-ziekte-vragenlijst-2017. Published 2017.